Arvinas Inc.

The momentum for this stock is not very good. Arvinas Inc. is not a good growth stock. Arvinas Inc. is not very popular among insiders. Arvinas Inc. is a mediocre stock to choose.

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commer...

News

Arvinas (NASDAQ:ARVN) Stock Rating Reaffirmed by Cantor Fitzgerald

Ticker Report Arvinas (NASDAQ:ARVN - Get Free Report)s stock had its "overweight" rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga...\n more…

Arvinas (NASDAQ:ARVN) Given Overweight Rating at Cantor Fitzgerald

Zolmax Cantor Fitzgerald reissued their overweight rating on shares of Arvinas (NASDAQ:ARVN - Free Report) in a research report report published on Monday morning, Benzinga reports.\nOther analysts have...\n more…

Numerous Arvinas Insiders Sold Stock: Not A Positive Omen

Simply Wall St A number of Arvinas, Inc. ( NASDAQ:ARVN ) insiders sold their shares in the last year, which may have raised concerns...\n more…

Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by Allspring Global Investments Holdings LLC

Ticker Report Allspring Global Investments Holdings LLC raised its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 13.7% during the 2nd quarter, according to the company in its most recent filing with the...\n more…

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 11.4% in August

Ticker Report Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totalling 11,950,000 shares, an...\n more…

Arvinas to Participate in Upcoming Investor Conferences

Globe Newswire NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...\n more…